Ken Griffin Ardelyx, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.28 - $7.57 $777,216 - $1.11 Million	147,200 Added 76.03%	340,800 $2.35 Million
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.31 $381,672 - $603,288	-64,800 Reduced 25.08%	193,600 $1.43 Million
Q1 2024 May 15, 2024	SELL	$6.05 - $9.74 $369,655 - $595,114	-61,100 Reduced 19.12%	258,400 $1.89 Million
Q4 2023 Feb 14, 2024	BUY	$3.29 - $6.64 $664,909 - $1.34 Million	202,100 Added 172.15%	319,500 $1.98 Million
Q3 2023 Nov 14, 2023	SELL	$3.3 - $4.83 $278,190 - $407,169	-84,300 Reduced 41.79%	117,400 $478,000
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $234,821 - $359,865	-72,700 Reduced 26.49%	201,700 $683,000
Q1 2023 May 15, 2023	SELL	$2.68 - $4.79 $253,796 - $453,613	-94,700 Reduced 25.66%	274,400 $1.31 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $136,640 - $319,200	112,000 Added 43.56%	369,100 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $66,965 - $163,440	113,500 Added 79.04%	257,100 $306,000

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $804M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.